Clobetasol propionate shampoo 0.05% in the treatment of seborrheic dermatitis of the scalp: Results of a pilot study

Cutis

Volumn 79, Issue 5, 2007, Pages 397-403

  Reygagne, Pascal ^a   Poncet, Michel ^b   Sidou, Farzaneh ^b   Soto, Pascale ^b  

^a Galderma R and D ^*

^b Galderma R and D   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; CLOBETASOL; COSMETIC;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HOSPITALIZATION; HUMAN; INTRADERMAL DRUG ADMINISTRATION; MALE; MULTICENTER STUDY; PATHOLOGY; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; SEBORRHEIC DERMATITIS; SINGLE BLIND PROCEDURE; SKIN DISEASE; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; ADULT; ANTI-INFLAMMATORY AGENTS; CLOBETASOL; DERMATITIS, SEBORRHEIC; FEMALE; HAIR PREPARATIONS; HUMANS; MALE; PILOT PROJECTS; SCALP DERMATOSES; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 34250630592     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Gupta AK, Bluhm R. Seborrheic dermatitis. J Eur Acad Dermatol Venereol. 2004;18:13-26.
2. Kligman AM, McGinley KJ, Leyden JL. The nature of dandruff. J Cosmet Chem. 1976;27:111-139.
3. Farthing CF, Staughton RC, Rowland Payne CM. Skin disease in homosexual patients with acquired immune deficiency syndrome (AIDS) and lesser forms of human T cell leukaemia virus (HTLV III) disease. Clin Exp Dermatol. 1985;10: 3-12.
4. Smith KJ, Skelton HG, Yeager J, et al, for the Military Medical Consortium for the Advancement of Retroviral Research (MMCARR). Cutaneous findings in HIV-1 positive patients: a 42-month prospective study. J Am Acad Dermatol. 1994;31:746-754.
5. Wikler JR, Neboer C, Willemze R. Quantitative skin cultures of Pityrosporum yeasts in patients seropositive for the human immunodeficiency virus with and without seborrheic dermatitis. J Am Acad Dermatol. 1992;27: 37-39.
6. Bergbrant IM, Faergemann J. Seborrheic dermatitis and Pityrosporum ovale: a cultural and immunological study. Acta Derm Venereol. 1989;69:332-335.
7. Parry ME, Sharpe GR. Seborrheic dermatitis is not caused by an altered immune response to Malassezia yeast. Br J Dermatol. 1998;139:254-263.
8. Gueho E, Midgley G, Guillot J. The genus Malassezia with description of four new species. Antonie Van Leeuwenhoek. 1996;69:337-355.
9. Faergemann J. Pityrosporum species as a cause of allergy and infection. Allergy. 1999;54:413-419.
10. Gupta AK, Bluhm R, Cooper EA, et al. Seborrheic dermatitis. Dermatol Clin. 2003;21:401-412.
11. Quéreux G, Dréno B, Chosidow O. Treatment of seborrheic dermatitis [in French]. Ann Dermatol Venereol. 2004;131 (1 pt 2):130-134.
12. Shemer A, Nathansohn N, Kaplan B, et al. Treatment of scalp seborrheic dermatitis and psoriasis with ointment of 40% urea and 1% bifonazole. Int J Dermatol. 2000;39: 521-539.
13. Parsad D, Pandhi R, Negi KS, et al. Topical metronidazole in seborrheic dermatitis - a double-blind study. Dermatology. 2001;202:35-37.
14. Johnson BA, Nunley JR. Treatment of seborrheic dermatitis. Am Fam Physician. 2000;61:2703-2710, 2713-2714.
15. Crutchfield CE III. Pimecrolimus: a new treatment for seborrheic dermatitis. Cutis. 2002;70:207-208.
16. Squire RA, Good K. A randomised, single-blind, single centre clinical trial to evaluate comparative clinical efficacy of shampoos containing ciclopirox olamine (1.5%) and salicylic acid (3%), or ketoconazole (2%, Nizoral) for the treatment of dandruff/seborrheic dermatitis. J Dermatolog Treat. 2002;13:51-60.
17. Cassano N, Amourose A, Loconsole F, et al. Oral terbinafine for the treatment of seborrheic dermatitis in adults. J Dermatolog Treat. 2002;41:821-822.
18. Peter RU, Richartz-Barthauer U. Successful treatment and prophylaxis of scalp seborrheic dermatitis and dandruff with 2% ketoconazole shampoo: results of a multicentre, double blind, placebo-controlled trial. Br J Dermatol. 1995;132:441-445.
19. Pierard-Franchimont C, Piérard GE, Arrese JE, et al. Effect of ketoconazole 1% and 2% shampoos on severe dandruff and seborrheic dermatitis: clinical, squamometric and mycological assessments. Dermatology. 2001;202:171-176.
20. Ortonne JP, Lacour JP, Vietta A, et al. Comparative study of ketoconazole 2% foaming gel and betamethasone diproprionate 0.05% lotion in the treatment of seborrheic dermatitis in adults. Dermatology. 1992;184: 275-280.
21. Stratigos JD, Antoniou C, Katsambas A, et al. Ketoconazole 2% cream versus hydrocortisone 1% cream in the treatment of seborrheic dermatitis: a double-blind comparative study. J Am Acad Dermatol. 1988;19: 850-853.
22. Danby FW, Maddin WS, Margesson LJ, et al. A randomized, double-blind, placebo-controlled trial of ketoconazole 2% shampoo versus selenium sulfide 2.5% shampoo in the treatment of moderate to severe dandruff. J Am Acad Dermatol. 1993;29:1008-1012.
23. Aso M. The effects of potent topical corticosteroids on adrenocortical function. J Dermatol. 1983;10: 145-149.
24. Eriksen K. Comparison of clobetasol propionate and betamethasone-17,21- dipropionate with reference to adrenal suppression. Acta Derm Venereol. 1979;59:372-374.
25. Katz HI, Hien NT, Prawer SE, et al. Superpotent topical steroid treatment of psoriasis vulgaris - clinical efficacy and adrenal function. J Am Acad Dermatol. 1987;16:804-811.
26. Walsh P, Aeling JL, Huff L, et al. Hypothalamuspituitary-adrenal axis suppression by superpotent topical steroids. J Am Acad Dermatol. 1993;29:501-503.
27. Gilbertson EO, Spellman MC, Piacquadio DJ, et al. Super potent topical corticosteroid use associated with adrenal suppression: clinical considerations. J Am Acad Dermatol. 1998;38:318-321.
28. Data on file. Ocular safety and HPA axis suppresion potential of clobetasol propionate shampoo 0.05%-a study on both scalp psoriasis and scalp seborrheic dermatitis subjects. Sophia Antipolis, France: Galderma R&D; 2000.